VHL Antibody (C-term)

Synthetic Peptide

Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of VHL gene is the basis of familial inheritance of VHL syndrome. The protein is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein.

Polyclonal

7428

Purified Rabbit Polyclonal Antibody (Pab)

Anti-VHL Antibody (C-term) at 1:1000 dilution + Raji whole cell lysate

Lysates/proteins at 20 µg per lane.

Secondary
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution.

Predicted band size : 24 kDa

Blocking/Dilution buffer: 5% NFDM/TBST.

1:1000

WB

VHL Antibody (C-term) (RB18668) IHC analysis in formalin fixed and paraffin embedded mouse brain tissue followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of the VHL Antibody (C-term) for immunohistochemistry. Clinical relevance has not been evaluated.

1:50~100

FC

Rabbit Ig

181-210

This VHL antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 181-210 amino acids from the C-terminal region of human VHL.